Mersana Therapeutics MRSN Stock
Mersana Therapeutics Price Chart
Mersana Therapeutics MRSN Financial and Trading Overview
| Mersana Therapeutics stock price | 0.38 USD |
| Previous Close | 1.52 USD |
| Open | 1.52 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 1.47 - 1.58 USD |
| 52 Week Range | 1.07 - 6.28 USD |
| Volume | 479.9K USD |
| Avg. Volume | 1.36M USD |
| Market Cap | 193.83M USD |
| Beta (5Y Monthly) | 1.465 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.5 USD |
MRSN Valuation Measures
| Enterprise Value | 64.02M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.2253523 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.47448 |
| Price/Book (mrq) | 22.898552 |
| Enterprise Value/Revenue | 2.138 |
| Enterprise Value/EBITDA | -0.631 |
Trading Information
Mersana Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.465 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 6.28 USD |
| 52 Week Low | 1.07 USD |
| 50-Day Moving Average | 1.79 USD |
| 200-Day Moving Average | 2.81 USD |
MRSN Share Statistics
| Avg. Volume (3 month) | 1.36M USD |
| Avg. Daily Volume (10-Days) | 909.17K USD |
| Shares Outstanding | 122.68M |
| Float | 72.29M |
| Short Ratio | 6.16 |
| % Held by Insiders | 1.35% |
| % Held by Institutions | 94.63% |
| Shares Short | 8.49M |
| Short % of Float | 9.10% |
| Short % of Shares Outstanding | 6.91% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | June 30, 2024 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1110.11% |
| Gross Margin | -193.80% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.29% |
| Return on Equity (ttm) | -213.33% |
Income Statement
| Revenue (ttm) | 29.94M USD |
| Revenue Per Share (ttm) | 0.25 USD |
| Quarterly Revenue Growth (yoy) | -78.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | -101411000 USD |
| Net Income Avi to Common (ttm) | -104774000 USD |
| Diluted EPS (ttm) | -0.85 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 162.74M USD |
| Total Cash Per Share (mrq) | 1.33 USD |
| Total Debt (mrq) | 32.93M USD |
| Total Debt/Equity (mrq) | 390.8 USD |
| Current Ratio (mrq) | 2.717 |
| Book Value Per Share (mrq) | 0.069 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -132555000 USD |
| Levered Free Cash Flow (ttm) | -66514624 USD |
Profile of Mersana Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 840 Memorial Drive |
| ZIP | 02139 |
| Phone | 617 498 0020 |
| Website | https://www.mersana.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 123 |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Q&A For Mersana Therapeutics Stock
What is a current MRSN stock price?
Mersana Therapeutics MRSN stock price today per share is 0.38 USD.
How to purchase Mersana Therapeutics stock?
You can buy MRSN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mersana Therapeutics?
The stock symbol or ticker of Mersana Therapeutics is MRSN.
Which industry does the Mersana Therapeutics company belong to?
The Mersana Therapeutics industry is Biotechnology.
How many shares does Mersana Therapeutics have in circulation?
The max supply of Mersana Therapeutics shares is 124.63M.
What is Mersana Therapeutics Price to Earnings Ratio (PE Ratio)?
Mersana Therapeutics PE Ratio is now.
What was Mersana Therapeutics earnings per share over the trailing 12 months (TTM)?
Mersana Therapeutics EPS is -0.56 USD over the trailing 12 months.
Which sector does the Mersana Therapeutics company belong to?
The Mersana Therapeutics sector is Healthcare.
Mersana Therapeutics MRSN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.44B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.44B USD — |
| NASDAQ Global Select Market Com NQGS | 8452.28 USD — |
-0.61
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4158.56 USD — |
+0.66
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 925.29 USD — |
+0.19
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
- {{ link.label }} {{link}}